Revelation Biosciences, Inc. (REVB)

US — Healthcare Sector
Peers: VRAX  BWV  HILS  KPRX  ZVSA  SONN  NAVB  CYTO  ZURA  PHIO  RNAZ  QNRX  PXMD 

Automate Your Wheel Strategy on REVB

With Tiblio's Option Bot, you can configure your own wheel strategy including REVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REVB
  • Rev/Share 0.0
  • Book/Share 2.9658
  • PB 0.2967
  • Debt/Equity 0.0
  • CurrentRatio 3.6052
  • ROIC -2.8354

 

  • MktCap 848140.0
  • FreeCF/Share -23.9667
  • PFCF -0.0364
  • PE -0.0593
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.0122

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Revelation Biosciences, Inc. (REVB)

  • IPO Date 2020-11-17
  • Website https://www.revbiosciences.com
  • Industry Biotechnology
  • CEO Mr. James M. Rolke
  • Employees 8
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.